Predicted Efficacy of Once-Daily Extended-Release Oxcarbazepine (Oxtellar XR®) Monotherapy in Adults and Children with Partial-Onset Seizures: Exposure-Response Modeling and Simulation

Predicted Efficacy of Once-Daily Extended-Release Oxcarbazepine (Oxtellar XR®) Monotherapy in Adults and Children with Partial-Onset Seizures: Exposure-Response Modeling and Simulation

Shamia Faison,1 Roberto Gomeni,2 Shannon Mendes,1 Welton O’Neal,1 Stefan Schwabe,1 Azmi Nasser1 1Supernus Pharmaceuticals, Inc., Rockville, MD, USA; 2PharmacoMetrica, La Fouillade, FranceCorrespondence: Azmi NasserSupernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD 20850, U...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Faison S, Gomeni R, Mendes S, O'Neal W, Schwabe S, Nasser A
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2020
Materias:
oxcarbazepine
monotherapy
oxtellar
monohydroxy derivative
adjunctive therapy
Therapeutics. Pharmacology
RM1-950
Acceso en línea:https://doaj.org/article/775ab1524b2142b4a1084b0ad7db2d39
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/775ab1524b2142b4a1084b0ad7db2d39

Ejemplares similares